



May 28, 2014 13:23 ET

PeriRx LLC's Robust Product Pipeline Includes Salivary Test for Sjogren's Syndrome -- a Common Symptom of Rheumatoid Arthritis

HAVERTOWN, PA--(Marketwired - May 28, 2014) - PeriRx LLC, a premier developer of breakthrough, non-invasive, [salivary diagnostic technology](#), recently announced that it will be introducing a highly accurate and scientifically validated molecular biomarker test for the early detection of Sjogren's Syndrome by the end of 2014.

Sjögren's Syndrome is a systemic chronic inflammatory disorder in which the immune system attacks and damages the body's moisture-producing glands. This causes dryness of the eyes and mouth and is associated with a number of oral and ocular complications.

In addition, Sjögren's sufferers may experience pain, stiffness and swelling in the joints, rashes on the arms and legs related to vasculitis -- an inflammation of blood vessels. The lungs, liver and kidneys may become inflamed; some people develop tingling and numbness in the limbs because of neurological complications. The disease either exists by itself as primary Sjögren's, or as secondary Sjögren's, which develops in conjunction with other connective tissue disorders such as rheumatoid arthritis (RA) or Lupus.

Diagnosing Sjögren's Syndrome has always been difficult. The average time between onset of symptoms and diagnosis is six years and the symptoms are often attributed to other causes when the patient first visits their physician.

According to [PeriRx LLC's](#) CEO Stephen M. Swanick, "The [PeriRx Sjögren's Syndrome Test](#) not only represents a technological breakthrough that enables earlier diagnosis of the disease; it puts the dental professional on the front lines with medical doctors and medical specialists in the collaborative care of the patient."

As with all PeriRx [salivary tests](#) currently under development, the [PeriRx Sjögren's Syndrome Test](#) is based on a strong scientific foundation of NIH-funded research with initial discovery and pre-validation work by Dr. David Wong of the University of California at Los Angeles. These discriminatory [salivary biomarkers](#) have been clinically validated in multiple large trials

including studies in collaboration with the National Cancer Institute and with premiere US and international academic medical centers.

For more information, visit www.PeriRx.com. To become an early adopter of the salivary test, or to become an investor in PeriRx LLC, contact Stephen M. Swanick at 610-449-9625 or perirx@rcn.com.

About PeriRx LLC:

Based in Havertown, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, non-invasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.

The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.

PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong's firm RNAmETRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmETrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.